Diligence memo · auto-generated · as of July 2, 2026
Qool Therapeutics, Inc.
Qool Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Qool Therapeutics, Inc. operates in Pharma, based in MENLO PARK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Qool Therapeutics, Inc. has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2017-11-08.
Most recent recorded round closed around 2017-11-08.
Valuation (modeled)modeled
Provath models Qool Therapeutics, Inc. at approximately $432M (range $16M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.38× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 8.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 72% of Pharma peers (310 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: SpringWorks Therapeutics, LLC, Caliber Therapeutics, Inc., Rodin Therapeutics, Inc., SmartPharm Therapeutics, Inc., AffyImmune Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.